A Novel Initiative to Treat and Cure ALS
We are laying the foundation for game-changing participation by the world's leading pharmaceutical and medical research companies; in doing so, we are taking significant steps toward treatment—and a cure—for ALS About Us »
THE FUTURE » TARGET ALS PROVIDES AN ORGANIZATIONAL FRAMEWORK FOR THE WORLD'S LEADING ALS RESEARCHERS TO SHARE AND COORDINATE THEIR FINDINGS, SO THAT WE CAN MAKE PROGRESS TOWARD THERAPIES AND A CURE. —Dan Doctoroff

Resources available from Target ALS for academia and industry: Investigators retain ownership of data and intellectual property generated from use of Target ALS resources

NEW RESOURCE: Target ALS has generated the poly(GP)monoclonal antibody from two hybridoma clones and is making them available to the ALS research community worldwide. To learn more, click here: http://www.targetals.org/about-us/core_facilities.html

Human postmortem tissue: Multiple CNS sub-regions from ALS and control cases with detailed de-identified clinical and demographic information

(explore Target ALS human postmortem tissue inventory)


Whole genome sequenced dataset of post-mortem tissue samples: The samples are being RNA sequenced. To access the RNAseq data, please contact alsdata@nygenome.org

Human stem cell lines: Well-characterized iPSC lines from ALS and control cases with detailed de-identified clinical and demographic information

(search and order from Target ALS stem cell inventory)